

Autologous Dendritic Cell Vaccine For Recurrent Respiratory Papillomatosis (RRP) Patients

NCT07317154

Status	RECRUITING
Phase	Phase 1
Sponsor	Mayo Clinic
Enrollment	9 participants

Key Eligibility Criteria

Inclusion (22)

- Clinically confirmed diagnosis of recurrent respiratory papillomatosis.
- Patients with papillomas in the laryngeal mucosa at the time of recruitment and patients with records of recurrent papillomas in laryngeal mucosa at least once in the past 6-12 months at the time of recruitment. NOTE: The presence of papillomas in laryngeal mucosa or clinical records of the presence of papillomas in laryngeal mucosa is required.
- Human papilloma virus (HPV)6+ RRP in larynx
- ECOG (Eastern cooperative oncology group performance test) performance status 0 or 1 (Appendix I).
- The following laboratory values obtained d 28 days prior to apheresis.

... and 17 more (see full listing online)

Exclusion (10)

- Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens.
- Immunocompromised patients and patients known to be HIV positive and currently receiving antiretroviral therapy.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- Receiving any other approved or investigational agent (including immune checkpoint blockers, immune modulators, and therapeutic vaccine models) for recurrent respiratory papillomatosis patients which would be considered as a treatment for the papillomas in laryngeal mucosa d 6 months prior to study enrollment.
- Other active malignancy d 5 years prior to enrollment. NOTE: If there is a history or prior malignancy, with the exception of adequately treated basal cell or squamous cell carcinoma of the skin, they must not be receiving other specific treatment for their cancer within one year.

... and 5 more (see full listing online)

Locations (1 total)

Mayo Clinic in Arizona, Scottsdale, Arizona, United States

<https://clinicaltrials.gov/study/NCT07317154>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).